2 37e 6 8 10e 6 3 10e 5 breast cancer mcf7 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
92
Structured Review
ATCC
2 37e 6 8 10e 6 3 10e 5 breast cancer mcf7
2 37e 6 8 10e 6 3 10e 5 Breast Cancer Mcf7, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+37e+6+8+10e+6+3+10e+5+breast+cancer+mcf7/Flexibacter+flexilis+Soriano/pm35097282__ao1c05743_si_003-4-413-435
Average 92 stars, based on 10 article reviews
2 37e 6 8 10e 6 3 10e 5 Breast Cancer Mcf7, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+37e+6+8+10e+6+3+10e+5+breast+cancer+mcf7/Flexibacter+flexilis+Soriano/pm35097282__ao1c05743_si_003-4-413-435
Average 92 stars, based on 10 article reviews
2 37e 6 8 10e 6 3 10e 5 breast cancer mcf7 - by Bioz Stars,
2026-09
92/100 stars
Images
Related Articles
Multiple Displacement Amplification:Article Title: Synthesis and Biological Evaluation of Novel 1 H -Benzo[ d ]imidazole Derivatives as Potential Anticancer Agents Targeting Human Topoisomerase I Article Snippet: .. MALME-3M 0.643 1.626 1.504 1.347 0.734 0.053 0.181 88 72 9 -92 -72 2.22E-7 1.23E-6 3.86E-6 M14 0.450 1.837 1.732 1.771 1.089 0.303 0.142 92 95 46 -33 -69 8.31E-7 3.84E-6 3.03E-5 MDA-MB-435 0.798 3.032 2.980 3.027 1.929 0.130 0.086 98 100 51 -84 -89 1.01E-6 2.38E-6 5.61E-6 SK-MEL-2 1.024 1.985 1.919 2.049 1.750 0.295 0.384 93 107 76 -71 -63 1.49E-6 3.27E-6 7.17E-6 SK-MEL-28 0.767 2.144 2.230 2.134 1.332 0.152 0.169 106 99 41 -80 -78 7.01E-7 2.18E-6 5.64E-6 SK-MEL-5 0.814 3.246 3.162 3.118 2.328 0.431 0.202 97 95 62 -47 -75 1.29E-6 3.71E-6 1.27E-5 UACC-257 1.423 2.848 2.769 2.842 2.294 1.009 0.747 94 100 61 -29 -48 1.33E-6 4.76E-6 > 1.00E-4 UACC-62 0.891 2.916 2.891 2.758 1.701 0.381 0.323 99 92 40 -57 -64 6.43E-7 2.58E-6 8.42E-6 Ovarian Cancer IGROV1 0.486 2.087 2.093 2.204 1.746 0.386 0.336 100 107 79 -21 -31 1.94E-6 6.20E-6 > 1.00E-4 OVCAR-3 0.718 1.947 1.906 2.167 1.139 0.379 0.093 97 118 34 -47 -87 6.49E-7 2.63E-6 1.17E-5 OVCAR-4 1.212 2.409 2.367 2.385 2.224 1.005 0.504 96 98 85 -17 -58 2.19E-6 6.79E-6 6.24E-5 OVCAR-5 0.669 1.501 1.448 1.492 1.611 0.790 0.133 94 99 113 14 -80 4.37E-6 1.42E-5 4.80E-5 OVCAR-8 0.656 2.683 2.648 2.768 2.354 0.741 0.513 98 104 84 4 -22 2.66E-6 1.45E-5 > 1.00E-4 NCI/ADR-RES 0.617 2.212 2.192 2.274 2.204 2.029 1.745 99 104 99 89 71 > 1.00E-4 > 1.00E-4 > 1.00E-4 SK-OV-3 1.188 2.118 2.100 2.293 1.971 1.161 0.947 98 119 84 -2 -20 2.49E-6 9.41E-6 > 1.00E-4 Renal Cancer 786-0 0.725 2.403 2.229 2.315 2.149 0.544 0.323 90 95 85 -25 -56 2.08E-6 5.93E-6 6.60E-5 A498 0.986 1.862 1.796 1.791 1.586 0.639 0.211 92 92 68 -35 -79 1.51E-6 4.58E-6 2.19E-5 ACHN 0.339 1.377 1.345 1.435 1.309 0.476 0.073 97 106 93 13 -79 3.48E-6 1.39E-5 4.88E-5 CAKI-1 0.881 2.491 2.331 2.484 2.050 1.209 0.330 90 100 73 20 -63 2.71E-6 1.76E-5 7.05E-5 RXF 393 1.061 2.042 1.958 2.005 1.635 0.119 0.480 91 96 58 -89 -55 1.14E-6 2.49E-6 5.45E-6 SN12C 0.478 1.989 1.920 1.972 1.526 0.511 0.206 95 99 69 2 -57 1.94E-6 1.09E-5 7.61E-5 TK-10 1.288 1.991 1.807 1.955 2.101 1.520 0.993 74 95 116 33 -23 6.22E-6 3.89E-5 > 1.00E-4 UO-31 0.690 2.041 1.922 2.009 1.878 1.501 0.358 91 98 88 60 -48 1.24E-5 3.59E-5 > 1.00E-4 Prostate Cancer PC-3 0.438 1.760 1.676 1.679 1.216 0.455 0.089 94 94 59 1 -80 1.42E-6 1.04E-5 4.30E-5 DU-145 0.549 1.962 1.952 2.084 1.751 0.502 0.039 99 109 85 -9 -93 2.37E-6 8.10E-6 3.10E-5 Breast Cancer MCF7 0.430 2.651 2.397 2.356 1.186 0.275 0.230 89 87 34 -36 -47 |